BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28940304)

  • 21. Targeted mutation analysis of endometrial clear cell carcinoma.
    Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas.
    Shih IeM; Panuganti PK; Kuo KT; Mao TL; Kuhn E; Jones S; Velculescu VE; Kurman RJ; Wang TL
    Am J Pathol; 2011 Apr; 178(4):1442-7. PubMed ID: 21435433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
    Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
    Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
    McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
    J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic aberrations in carcinomas of the uterine corpus.
    Micci F; Teixeira MR; Haugom L; Kristensen G; Abeler VM; Heim S
    Genes Chromosomes Cancer; 2004 Jul; 40(3):229-46. PubMed ID: 15139002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma.
    Ashley CW; Da Cruz Paula A; Ferrando L; Gularte-Mérida R; Sebastiao APM; Brown DN; Gazzo AM; Pareja F; Stylianou A; Abu-Rustum NR; Reis-Filho JS; Buehler D; Weisman P; Chiang S; Weigelt B
    Histopathology; 2021 Aug; 79(2):176-186. PubMed ID: 33527450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
    Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
    Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas.
    McConechy MK; Hoang LN; Chui MH; Senz J; Yang W; Rozenberg N; Mackenzie R; McAlpine JN; Huntsman DG; Clarke BA; Gilks CB; Lee CH
    J Pathol Clin Res; 2015 Jul; 1(3):173-85. PubMed ID: 27499902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
    Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
    Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
    Shih IeM; Wang TL
    J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
    Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
    Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
    Menderes G; Clark M; Santin AD
    Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
    Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
    Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
    Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S
    Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.
    Hillion J; Roy S; Heydarian M; Cope L; Xian L; Koo M; Luo LZ; Kellyn K; Ronnett BM; Huso T; Armstrong D; Reddy K; Huso DL; Resar LMS
    Gynecol Oncol; 2016 Jun; 141(3):580-587. PubMed ID: 27001612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis.
    Romero-Pérez L; Castilla MÁ; López-García MÁ; Díaz-Martín J; Biscuola M; Ramiro-Fuentes S; Oliva E; Matias-Guiu X; Prat J; Cano A; Moreno-Bueno G; Palacios J
    Hum Pathol; 2013 Feb; 44(2):244-54. PubMed ID: 22974476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma.
    Gotoh O; Sugiyama Y; Takazawa Y; Kato K; Tanaka N; Omatsu K; Takeshima N; Nomura H; Hasegawa K; Fujiwara K; Taki M; Matsumura N; Noda T; Mori S
    Nat Commun; 2019 Oct; 10(1):4965. PubMed ID: 31672974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.